Hematologic Cancer News and Features

FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment

FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment

The US FDA granted approval to fostamatinib (Tavalisse), a kinase inhibitor, for the treatment of thrombocytopenia in patients with chronic IPT who have had an insufficient response to a previous treatment.

Elevated Pre-HCT Iron Levels Predictive of Worse Survival Outcomes in AML/MDS

Elevated Pre-HCT Iron Levels Predictive of Worse Survival Outcomes in AML/MDS

The ALLIVE trial sought to determine if eLPI levels were predictive of iron-related toxicity and mortality after HCT in patients with AML or MDS.

Patients Identify Critical Elements of Support in Hematologic Cancers

Patients Identify Critical Elements of Support in Hematologic Cancers

A cross-sectional study asked patients with hematologic cancers to name the components of care they felt were most crucial to their perception of optimal care.

Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms

Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms

Researchers investigated the antileukemic activity of metformin and ruxolitinib alone and in combination in patients with myeloproliferative neoplasms.

Bisphosphonate Therapy Underutilized in Multiple Myeloma Bone Disease Management

Bisphosphonate Therapy Underutilized in Multiple Myeloma Bone Disease Management

A retrospective study evaluated timing, frequency, dosing, and other factors related to bisphosphonate therapy in patients with multiple myeloma.

Self-efficacy Measure May Be Used to Drive Interventions Post-SCT in Hematologic Cancers

Self-efficacy Measure May Be Used to Drive Interventions Post-SCT in Hematologic Cancers

Researchers present findings of a study assessing the value of SESM evaluations in patients with hematologic cancer prior to undergoing SCT at the NACNS 2018 Annual Conference.

Cardiovascular Disease Risks Greater With ITP, Especially After Splenectomy

Cardiovascular Disease Risks Greater With ITP, Especially After Splenectomy

Idiopathic thrombocytopenic purpura (ITP) may be linked to an increased risk of cardiovascular disease, but studies have not been conclusive.

Pomalidomide Plus Dexamethasone Effective in R/R Multiple Myeloma

Pomalidomide Plus Dexamethasone Effective in R/R Multiple Myeloma

Researchers report on their findings of a retrospective study that compared pomalidomide plus dexamethasone vs dexamethasone alone in patients with relapsed/refractory multiple myeloma.

ITP Treatment Outcomes Not Improved With Intravenous vs Oral Corticosteroids

ITP Treatment Outcomes Not Improved With Intravenous vs Oral Corticosteroids

In this prospective study, researchers sought to compare the effectiveness of IV methylprednisolone vs oral prednisone in hospitalized patients with newly diagnosed ITP.

Shorter overall survival among patients with monoclonal gammopathy of undetermined significance

1. Patients diagnosed with monoclonal gammopathy of undetermined significance (MGUS) and followed for multiple decades showed shorter overall survival rates compared to matched controls. 2. Risk of progression to multiple myeloma or another blood cell disorder was associated with identified adverse risk factors. Evidence Rating: 1 (Excellent) Study Rundown: MGUS is a relatively common condition []

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs